Arlington Capital Partners Announces the Acquisition of Micron Technologies
News Mar 21, 2013
Headquartered in Malvern, PA, Micron is a leading global provider of particle size engineering and related analytical services to the pharmaceutical industry.
Micron focuses on solving the pharmaceutical industry’s most difficult bio-availability and drug delivery challenges through multiple particle size reduction technologies. The Company is the leading independent provider of micronization services for solubility enhancement of active pharmaceutical ingredients (“APIs”). Micron maintains state of the art facilities offering industry leading capabilities including distinctive containment technology for processing highly potent compounds. Micron’s personnel have unique expertise in jet milling, mechanical milling, containment processing and associated analytical services including material characterization testing and stability monitoring.
“Micron’s ability to provide leading bio-availability solutions across the drug development spectrum, from clinical phases to the commercial market, positions the Company as a trusted long-term partner with its pharmaceutical clients for their most demanding drug development needs,” said Matt Altman, a Partner at Arlington Capital Partners. “We are enthusiastic about building upon the Company’s leadership position and eager to continue to support the Company as it enhances and expands its global particle size engineering and analytical service offerings.”
Joseph Drost, CEO of Micron, commented, “We are extremely excited about our partnership with Arlington Capital. Arlington has a successful history of investing in healthcare and pharmaceutical services and shares our vision for growing Micron’s global capabilities and service offerings.
Arlington’s ability to provide significant strategic and capital support will further enable Micron to continue to expand our leading global position and better serve our worldwide pharmaceutical client base.”
David Wodlinger, a Principal at Arlington Capital said, “Micron is an ideal platform investment in a compelling growth industry and we look forward to working closely with the company’s management team to expand the business aggressively, both organically and through acquisition.”
Greenberg Traurig served as counsel to Arlington Capital Partners for the transaction. Fairmount Partners advised Micron on the transaction.
Cow Antibodies Yield Important Clues For Developing A Broadly Effective AIDS VaccineNews
The unexpected animal model is providing clues for important questions at a moment when new energy has infused HIV vaccine research.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018